Literature DB >> 29709260

Noninvasive PET Imaging of T cells.

Weijun Wei1, Dawei Jiang2, Emily B Ehlerding3, Quanyong Luo4, Weibo Cai5.   

Abstract

The rapidly evolving field of cancer immunotherapy recently saw the approval of several new therapeutic antibodies. Several cell therapies, for example, chimeric antigen receptor-expressing T cells (CAR-T), are currently in clinical trials for a variety of cancers and other diseases. However, approaches to monitor changes in the immune status of tumors or to predict therapeutic responses are limited. Monitoring lymphocytes from whole blood or biopsies does not provide dynamic and spatial information about T cells in heterogeneous tumors. Positron emission tomography (PET) imaging using probes specific for T cells can noninvasively monitor systemic and intratumoral immune alterations during experimental therapies and may have an important and expanding value in the clinic.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T cells; cancer; graft-versus-host disease (GVHD); immunotherapy; inflammation; positron emission tomography (PET); response prediction

Mesh：

Year:  2018        PMID： 29709260      PMCID： PMC6034116          DOI： 10.1016/j.trecan.2018.03.009

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  130 in total

Review 1.  Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis.

Authors:  Martin Schlesinger; Gerd Bendas
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 2.  Noninvasive cell-tracking methods.

Authors:  Moritz F Kircher; Sanjiv S Gambhir; Jan Grimm
Journal:  Nat Rev Clin Oncol       Date:  2011-09-27       Impact factor: 66.675

3.  Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Authors:  Alessandro Prestipino; Alica J Emhardt; Konrad Aumann; David O'Sullivan; Sivahari P Gorantla; Sandra Duquesne; Wolfgang Melchinger; Lukas Braun; Slavica Vuckovic; Melanie Boerries; Hauke Busch; Sebastian Halbach; Sandra Pennisi; Teresa Poggio; Petya Apostolova; Pia Veratti; Michael Hettich; Gabriele Niedermann; Mark Bartholomä; Khalid Shoumariyeh; Jonas S Jutzi; Julius Wehrle; Christine Dierks; Heiko Becker; Annette Schmitt-Graeff; Marie Follo; Dietmar Pfeifer; Jan Rohr; Sebastian Fuchs; Stephan Ehl; Frederike A Hartl; Susana Minguet; Cornelius Miething; Florian H Heidel; Nicolaus Kröger; Ioanna Triviai; Tilman Brummer; Jürgen Finke; Anna L Illert; Eliana Ruggiero; Chiara Bonini; Justus Duyster; Heike L Pahl; Steven W Lane; Geoffrey R Hill; Bruce R Blazar; Nikolas von Bubnoff; Erika L Pearce; Robert Zeiser
Journal:  Sci Transl Med       Date:  2018-02-21       Impact factor: 17.956

4.  Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET.

Authors:  Ken Matsui; Zheng Wang; Timothy J McCarthy; Paul M Allen; David E Reichert
Journal:  Nucl Med Biol       Date:  2004-11       Impact factor: 2.408

5.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

Review 6.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

7.  64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues.

Authors:  Kei Higashikawa; Katsuharu Yagi; Keiko Watanabe; Shinichiro Kamino; Masashi Ueda; Makoto Hiromura; Shuichi Enomoto
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

Review 8.  Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.

Authors:  Sonja Schelhaas; Kathrin Heinzmann; Vikram R Bollineni; Gerbrand M Kramer; Yan Liu; John C Waterton; Eric O Aboagye; Anthony F Shields; Dmitry Soloviev; Andreas H Jacobs
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

9.  Cre/lox-assisted non-invasive in vivo tracking of specific cell populations by positron emission tomography.

Authors:  Martin Thunemann; Barbara F Schörg; Susanne Feil; Yun Lin; Jakob Voelkl; Matthias Golla; Angelos Vachaviolos; Ursula Kohlhofer; Leticia Quintanilla-Martinez; Marcus Olbrich; Walter Ehrlichmann; Gerald Reischl; Christoph M Griessinger; Harald F Langer; Meinrad Gawaz; Florian Lang; Michael Schäfers; Manfred Kneilling; Bernd J Pichler; Robert Feil
Journal:  Nat Commun       Date:  2017-09-05       Impact factor: 14.919

10.  Graft versus host disease in the bone marrow, liver and thymus humanized mouse model.

Authors:  Matthew B Greenblatt; Vladimir Vrbanac; Vladimir Vbranac; Trevor Tivey; Kelly Tsang; Andrew M Tager; Antonios O Aliprantis
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240
View more
  37 in total

1.  ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053.

Authors:  Cheng Wang; Yumei Chen; Yun Nan Hou; Qiufang Liu; Di Zhang; Haitao Zhao; You Zhang; Shuxian An; Lianghua Li; Jian Hou; Gang Huang; Jianjun Liu; Yong Juan Zhao; Weijun Wei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-05       Impact factor: 9.236

Review 2.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

3.  Decoding the Body Language of Immunity: Tackling the Immune System at the Organism Level.

Authors:  Nicolas Chevrier
Journal:  Curr Opin Syst Biol       Date:  2019-11-06

4.  Development and characterization of CD54-targeted immunoPET imaging in solid tumors.

Authors:  Weijun Wei; Dawei Jiang; Hye Jin Lee; Miao Li; Christopher J Kutyreff; Jonathan W Engle; Jianjun Liu; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-11       Impact factor: 9.236

5.  The Production, Quality Control, and Characterization of ZED8, a CD8-Specific 89Zr-Labeled Immuno-PET Clinical Imaging Agent.

Authors:  Herman Gill; Richard Seipert; Vincent M Carroll; Alexandra Gouasmat; Jian Yin; Annie Ogasawara; Isabella de Jong; Minh Michael Phan; Xiangdan Wang; Jihong Yang; Ohad Ilovich; Jan Marik; Simon-Peter Williams
Journal:  AAPS J       Date:  2020-01-03       Impact factor: 4.009

Review 6.  Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology.

Authors:  DaeHee Kim; Joseph P Erinjeri
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

7.  ImmunoPET Imaging of TIM-3 in Murine Melanoma Models.

Authors:  Weijun Wei; Dawei Jiang; Hye Jin Lee; Jonathan W Engle; Hisaya Akiba; Jianjun Liu; Weibo Cai
Journal:  Adv Ther (Weinh)       Date:  2020-04-17

Review 8.  Clinical correlates for immune checkpoint therapy: significance for CNS malignancies.

Authors:  Nivedita M Ratnam; Stephen C Frederico; Javier A Gonzalez; Mark R Gilbert
Journal:  Neurooncol Adv       Date:  2020-11-27

9.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

10.  A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4.

Authors:  Anna Moroz; Chia-Yin Lee; Yung-Hua Wang; Jeffrey C Hsiao; Natalia Sevillano; Charles Truillet; Charles S Craik; Lawrence Fong; Cheng-I Wang; Michael J Evans
Journal:  Bioconjug Chem       Date:  2018-09-24       Impact factor: 4.774
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.